Cardiol Therapeutics (STU:CT9) Other Stockholders Equity: €1.78 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:CT9 Cardiol Therapeutics Inc STU:CT9
40 GF Score
Price €0.99
! 3 Warning Signs
View Full Analysis

What is Cardiol Therapeutics Other Stockholders Equity?

Cardiol Therapeutics STU:CT9 +8.17% 40 Other Stockholders Equity is €1.78 Mil as of Mar. 2026. GuruFocus rates STU:CT9 with a GF Score™ of 40/100. The stock has 3 warning signs investors should review.

Cardiol Therapeutics's Other Stockholders Equity for the quarter that ended in Mar. 2026 was €1.78 Mil.

Cardiol Therapeutics's quarterly Other Stockholders Equity increased from Sep. 2025 (€-0.00 Mil) to Dec. 2025 (€0.00 Mil) and increased from Dec. 2025 (€0.00 Mil) to Mar. 2026 (€1.78 Mil).

Cardiol Therapeutics's annual Other Stockholders Equity declined from Dec. 2023 (€2.41 Mil) to Dec. 2024 (€0.00 Mil) and declined from Dec. 2024 (€0.00 Mil) to Dec. 2025 (€0.00 Mil).

Cardiol Therapeutics Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Cardiol Therapeutics's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cardiol Therapeutics Other Stockholders Equity Chart

Cardiol Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only 2.89 2.44 2.41 0.00 0.00

Cardiol Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.00 -0.00 0.00 1.78
STU:CT9
40GF Score
Cardiol Therapeutics Inc STU:CT9
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cardiol Therapeutics Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of €1.78 Mil mean?
Cardiol Therapeutics (STU:CT9) has a Other Stockholders Equity of €1.78 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Cardiol Therapeutics and its competitors.
Is Cardiol Therapeutics' Other Stockholders Equity too high?
Cardiol Therapeutics' current Other Stockholders Equity is €1.78 Mil. Overall, Cardiol Therapeutics has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does Cardiol Therapeutics' Other Stockholders Equity compare to ZTS and UTHR?
Cardiol Therapeutics' Other Stockholders Equity of €1.78 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Cardiol Therapeutics and its competitors. Cardiol Therapeutics's current Other Stockholders Equity is €1.78 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiol Therapeutics stock overvalued right now?
Cardiol Therapeutics (STU:CT9) has a current Other Stockholders Equity of €1.78 Mil. The current Other Stockholders Equity is €1.78 Mil. Cardiol Therapeutics' overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Cardiol Therapeutics (STU:CT9), the current Other Stockholders Equity is €1.78 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cardiol Therapeutics Business Description

Other Exchanges CRDL:USACRDL:Canada
Address 2265 Upper Middle Road East, Suite 602, Oakville, ON, CAN, L6H 0G5
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.
40GF Score

Get the complete analysis for STU:CT9

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.99
Price